Vaccines

High pneumococcal community-acquired pneumonia burden in older adults highlights the critical role of pharmacists in driving 21-valent vaccine uptake and patient-centered prevention strategies.

New evidence shows that human papillomavirus (HPV) 9-valent vaccine protection lasts up to 14 years. Learn why early vaccination and pharmacists can boost cancer prevention.

The influenza vaccine halves the risk of heart attack and stroke after infection, offering cardiovascular protection even when breakthrough influenza occurs.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

At APhA 2026, Damika Walker, PharmD, RPh, argued that closing stubbornly low adult vaccination rates requires a shift in how pharmacists approach every patient encounter.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

Jacinda “JAM" Abdul-Mutakabbir, PharmD, MPH, discusses the adult burden of respiratory syncytial virus (RSV) and the critical role of pharmacists in vaccine access and education—especially for marginalized populations.

Late-stage Lyme disease vaccine candidate VLA15 boosts immunization hopes as tick infections rise.

Sharon Nachman, MD, equips pharmacists with clear, evidence-based talking points to address vaccine hesitancy and help parents navigate the confusion created by the legal battle over childhood immunization schedules.

Respiratory syncytial virus hits older adults hard and is often missed. Learn symptoms, testing, and how new vaccines and pharmacists help prevent severe illness.

Sharon Nachman, MD, division chief for pediatric infectious disease at Stony Brook Children's Hospital, shares her reaction to the court ruling blocking the scaled-back childhood vaccine schedule.

Dual-target flu immunity to HA and NA halves airborne spread in ferrets without escape mutations, reshaping next-generation vaccines and pharmacist counseling.

A federal judge halted HHS Secretary Robert F. Kennedy Jr's rollback of childhood vaccines, freezing ACIP's overhaul and immunization votes amid a medical society lawsuit.

FDA expands Arexvy RSV vaccine to at-risk adults 18-49, backed by phase 3b data—what it means for patients and pharmacists.

Ongoing measles outbreaks highlight the impacts of reduced vaccination rates and heightened public distrust in health experts.

Stable HCV E1E2 proteins on self-assembling nanoparticles spark strong mouse antibodies, advancing a long-sought hepatitis C vaccine.

A preclinical mucosal C difficile vaccine clears spores and prevents recurrence in animals, hinting at new protection for high‑risk patients.

The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."

To combat vaccine-related misinformation and disinformation, the speakers emphasize the importance of integrated education, community-led advocacy, and proactive outreach.

As the spring travel season approaches, more than 30 countries appear on the CDC's circulating polio alert list.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

Learn how COVID-19 drives heart and vascular risks, why vaccines and antivirals help, and how pharmacists manage dangerous drug interactions.